Amneal Pharmaceuticals, Inc.
AMRX
$1.31
$0.043.15%
| 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | |
|---|---|---|---|---|---|
| Revenue | 609.76M | 545.56M | 559.36M | 497.63M | 536.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 609.76M | 545.56M | 559.36M | 497.63M | 536.90M |
| Cost of Revenue | 390.41M | 352.06M | 354.55M | 323.83M | 349.63M |
| Gross Profit | 219.35M | 193.49M | 204.81M | 173.81M | 187.26M |
| SG&A Expenses | 102.16M | 100.07M | 98.81M | 98.67M | 97.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.47M | -1.32M | -1.18M | -- | -- |
| Total Operating Expenses | 533.01M | 501.05M | 502.92M | 475.29M | 498.73M |
| Operating Income | 76.75M | 44.51M | 56.43M | 22.34M | 38.17M |
| Income Before Tax | -7.66M | 2.18M | -232.73M | -9.92M | -16.32M |
| Income Tax Expenses | -1.80M | 4.57M | 7.35M | -3.46M | 4.14M |
| Earnings from Continuing Operations | -5.86M | -2.39M | -240.08M | -6.46M | -20.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.53M | -299.00K | 119.27M | 4.30M | 14.08M |
| Net Income | -4.33M | -2.69M | -120.81M | -2.16M | -6.38M |
| EBIT | 76.75M | 44.51M | 56.43M | 22.34M | 38.17M |
| EBITDA | 137.81M | 106.12M | 116.13M | 80.16M | 99.35M |
| EPS Basic | -0.03 | -0.02 | -0.80 | -0.01 | -0.04 |
| Normalized Basic EPS | 0.15 | 0.01 | 0.88 | -0.02 | 0.14 |
| EPS Diluted | -0.03 | -0.02 | -0.80 | -0.01 | -0.04 |
| Normalized Diluted EPS | 0.15 | 0.01 | 0.88 | -0.02 | 0.14 |
| Average Basic Shares Outstanding | 151.48M | 151.39M | 150.99M | 149.89M | 149.38M |
| Average Diluted Shares Outstanding | 151.48M | 151.39M | 150.99M | 149.89M | 149.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
